
Tatyana A Feldman MD
Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
Physician
Join to view full profile
92 2nd StHackensack, NJ 07601
Phone+1 551-996-3033
Fax+1 551-996-0573
Dr. Feldman is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- As an attending physician in the Lymphoma Division and director of the T-Cell Lymphoma Program at John Theurer Cancer Center, I am optimistic that current research into intercellular mechanisms can generate effective new therapies for treating this rare type of lymphoma. Immunotherapy, specifically CAR-T 19 cells that are genetically modified to attack lymphoma cells, is an especially exciting new approach.
Education & Training
NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2000 - 2001
NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 1999 - 2000
Icahn School of Medicine at Mount Sinai/Beth IsraelResidency, Internal Medicine, 1995 - 1999
Minsk Medical InstituteClass of 1992
Certifications & Licensure
NY State Medical License 1998 - 2028
DC State Medical License 2019 - 2027
NJ State Medical License 2002 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
Clinical Trials
Publications & Presentations
PubMed
- Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004.William G Wierda, Kathleen Dorritie, Jordan Gauthier, Rajneesh Nath, Thomas J Kipps
Blood. 2026-11-12 - Nivolumab with doxorubicin, vinblastine, and dacarbazine in older adults with classic Hodgkin lymphoma: do S1826 results hold up in the real world?Pallawi Torka, Allison M Bock, Peirong Hao, Yizhe Xu, Swetha K Thiruvengadam
Haematologica. 2026-10-08 - Real-World Experience With TRBC1 Immunohistochemistry Across Cutaneous T-Cell Lymphoma Subtypes: A Large Cohort Study.Anna Sarah Erem, Nicollette Pepin, Yoni Sacknovitz, Joshua A Kent, Seda S Tolu
Modern Pathology. 2026-10-01
Abstracts/Posters
- Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Mu...Tatyana A. Feldman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malig...Tatyana A. Feldman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...Tatyana A. Feldman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Cost-Effectiveness of brentuximab vedotin with chemotherapy in frontline treatment of CD30-expressing peripheral T-cell lymphoma.2019 ASCO Annual Meeting - 6/1/2019
- Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Elevated IL-1Ra Levels in the Stem Cell Product Is Associated with the Development of Engraftment Syndrome Following Autologous Stem Cell Transplantation for the Treat...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
2022 N.J. Top Cancer Doctors Deliver Quality and Compassionate Care, Close to HomeJune 16th, 2022
N.J.’s 2021 Top Cancer Doctors Lead Charge to Help Patients Thrive and Survive After PandemicJune 17th, 2021
John Theurer Cancer Center's Dr. Andre Goy Co-Chairs 21st Annual International Congress on Hematologic MalignanciesFebruary 27th, 2017
Professional Memberships
- Member
- Member
- Member
Other Languages
- Russian
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
